Publications: Cefiderocol

  • Effect of Cefiderocol, a Siderophore Cephalosporin, on QT/QTc Interval in Healthy Adult Subjects

    Clinical Therapeutics.

    Sanabria C<sup>1</sup>, Migoya E<sup>2</sup>, Mason JW<sup>3</sup>, Stanworth SH<sup>4</sup>, Katsube T<sup>5</sup>, Machida M<sup>5</sup>, Narukawa Y<sup>5</sup>, Den Nagata T<sup>5</sup>.

    <sup>1</sup>Spaulding Clinical Research, LLC, West Bend, Wisconsin, USA; <sup>2</sup>Shionogi Inc, Florham Park, New Jersey, USA; <sup>3</sup>Mason Cardiac Safety Consulting, Reno, Nevada, USA; <sup>4</sup>Spaulding Clinical Research, LLC, West Bend, Wisconsin, USA; <sup>5</sup>Shionogi & Co, Ltd, Osaka, Japan.

  • In vivo pharmacodynamic study of cefiderocol, a novel parenteral siderophore cephalosporin, in murine thigh and lung infection models

    Antimicrobial Agents and Chemotherapy.

    Nakamura R<sup>1</sup>, Ito-Horiyama T<sup>2</sup>, Takemura M<sup>2</sup>, Toba S<sup>2</sup>, Matsumoto S<sup>2</sup>, Ikehara T<sup>2</sup>, Tsuji M<sup>2</sup>, Sato T<sup>2</sup>, Yamano Y<sup>2</sup>.

    <sup>1</sup>Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd, Toyonaka, Osaka 561-0825, Japan; <sup>2</sup>Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd, Toyonaka, Osaka 561-0825, Japan.

  • Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects

    Journal of Antimicrobial Chemotherapy.

    Katsube T<sup>1</sup>, Saisho Y<sup>2</sup>, Shimada J<sup>3</sup>, Furuie H<sup>4</sup>.

    <sup>1</sup>Clinical Pharmacology & Pharmacokinetics, Shionogi & Co., Ltd, Osaka, Japan; <sup>2</sup>Medical Affairs Department, Shionogi & Co., Ltd, Osaka, Japan; <sup>3</sup>St Marianna University School of Medicine, Kawasaki, Japan; <sup>4</sup>Osaka Pharmacology Clinical Research Hospital, Osaka, Japan.

  • Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth

    Diagnostic Microbiology and Infectious Disease.

    Hackel MA<sup>1</sup>, Tsuji M<sup>2</sup>, Yamano Y<sup>3</sup>, Echols R<sup>4</sup>, Karlowsky JA<sup>5</sup>, Sahm DF<sup>6</sup>.

    <sup>1</sup>International Health Management Associates, Inc., Schaumburg, Illinois, USA; <sup>2</sup>Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd., Osaka, Japan; <sup>3</sup>Pharmaceutical Research Division, Shionogi & Co., Ltd., Osaka, Japan; <sup>4</sup>Clinical Development and Medical Affairs, ID3C, LLC, Easton, Connecticut, USA; <sup>5</sup>Department of Medical Microbiology and Infectious Diseases, College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada; <sup>6</sup>International Health Management Associates, Inc., Schaumburg, Illinois, USA.

  • Metabolism, Excretion, and Pharmacokinetics of [14C]-Cefiderocol (S-649266), a Siderophore Cephalosporin, in Healthy Subjects Following Intravenous Administration

    The Journal of Clinical Pharmacology.

    Miyazaki S<sup>1</sup>, Katsube T<sup>1</sup>, Shen H<sup>2</sup>, Tomek C<sup>3</sup>, Narukawa Y<sup>1</sup>.

    <sup>1</sup>Shionogi & Co., Ltd., Osaka, Japan; <sup>2</sup>QPS, LLC, Newark, Delaware, USA; <sup>3</sup>Celerion, Lincoln, Nebraska, USA.

  • Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli

    Drugs.

    Zhanel GG<sup>1,2</sup>, Golden AR<sup>3</sup>, Zelenitsky S<sup>4</sup>, Wiebe K<sup>4</sup>, Lawrence CK<sup>4</sup>, Adam HJ<sup>3,5</sup>, Idowu T<sup>6</sup>, Domalaon R<sup>6</sup>, Schweizer F<sup>3,6</sup>, Zhanel MA<sup>3</sup>, Lagacé-Wiens PRS<sup>3,5</sup>, Walkty AJ<sup>3,5</sup>, Noreddin A<sup>7</sup>, Lynch Iii JP<sup>8</sup>, Karlowsky JA<sup>3,5</sup>.

    <sup>1</sup>Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada; <sup>2</sup>Clinical Microbiology, Health Sciences Centre, MS673-820 Sherbrook Street, Winnipeg, Manitoba, R3A 1R9, Canada; <sup>3</sup>Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada; <sup>4</sup>College of Pharmacy, Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada; <sup>5</sup>Diagnostic Services, Shared Health, Winnipeg, MB, Canada; <sup>6</sup>Department of Chemistry, Faculty of Science, University of Manitoba, Winnipeg, MB, Canada; <sup>7</sup>College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates; <sup>8</sup>Division of Pulmonary, Critical Care, Allergy and Clinical Immunology, The David Geffen School of Medicine at UCLA, Los Angeles, California, USA.

  • Efficacy of Humanized Cefiderocol Exposures over 72 Hours against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model

    Antimicrobial Agents and Chemotherapy.

    Stainton SM<sup>1,2</sup>, Monogue ML<sup>1</sup>, Tsuji M<sup>3</sup>, Yamano Y<sup>3</sup>, Echols R<sup>4</sup>, Nicolau DP<sup>5,6</sup>.

    <sup>1</sup>Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA; <sup>2</sup>Lake Erie College of Osteopathic Medicine, School of Pharmacy, Erie, Pennsylvania, USA; <sup>3</sup>Shionogi & Co., Ltd., Osaka, Japan; <sup>4</sup>ID3C, LLC, Easton, Connecticut, USA; <sup>5</sup>Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA; <sup>6</sup>Division of Infectious Diseases, Hartford Hospital, Hartford, Connecticut, USA.

  • In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015

    International Journal of Antimicrobial Agents.

    Karlowsky JA<sup>1</sup>, Hackel MA<sup>2</sup>, Tsuji M<sup>3</sup>, Yamano Y<sup>4</sup>, Echols R<sup>5</sup>, Sahm DF<sup>6</sup>.

    <sup>1</sup>International Health Management Associates, Inc., Schaumburg, Illinois, USA; Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada; <sup>2</sup>International Health Management Associates, Inc., Schaumburg, Illinois, USA; <sup>3</sup>Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd., Osaka, Japan; <sup>4</sup>Pharmaceutical Research Division, Shionogi & Co., Ltd., Osaka, Japan; <sup>5</sup>Clinical Development and Medical Affairs, ID3C, LLC, Easton, Connecticut, USA; <sup>6</sup>International Health Management Associates, Inc., Schaumburg, Illinois, USA.

  • Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa

    Clinical Infectious Diseases.

    Edgeworth JD<sup>1</sup>, Merante D<sup>2</sup>, Patel S<sup>2</sup>, Young C<sup>3</sup>, Jones P<sup>4</sup>, Vithlani S<sup>5</sup>, Wyncoll D<sup>3</sup>, Roberts P<sup>3</sup>, Jones A<sup>3</sup>, Den Nagata T<sup>6</sup>, Ariyasu M<sup>6</sup>, Livermore DM<sup>7,8</sup>, Beale R<sup>9</sup>.

    <sup>1</sup>Department of Infectious Diseases, Guy’s Hospital, Kings College London, London, United Kingdom; <sup>2</sup>Shionogi Limited, Global Clinical Development Unit, London, United Kingdom; <sup>3</sup>Intensive Care Unit, London Bridge Hospital, HCA International, London, United Kingdom; <sup>4</sup>Microbiology Department, HCA International, London, United Kingdom; <sup>5</sup>Pharmacy Department, London Bridge Hospital, HCA International, London, United Kingdom; <sup>6</sup>Shionogi & Co., Ltd., Kitaku, Osaka, Japan; <sup>7</sup>Norwich Medical School, University of East Anglia, United Kingdom; <sup>8</sup>Antimicrobial Resistance & Healthcare Associated Infections Reference Unit, Public Health England, Colindale, London; <sup>9</sup>School of Medicine, Guy’s Hospital, Kings College London, United Kingdom.

  • In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)

    International Journal of Antimicrobial Agents.

    Kazmierczak KM<sup>1</sup>, Tsuji M<sup>2</sup>, Wise MG<sup>3</sup>, Hackel M<sup>3</sup>, Yamano Y<sup>4</sup>, Echols R<sup>5</sup>, Sahm DF<sup>3</sup>.

    <sup>1</sup>International Health Management Associates, Inc., Schaumburg, Illinois, United States; <sup>2</sup>Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd., Osaka, Japan; <sup>3</sup>International Health Management Associates, Inc., Schaumburg, Illinois, United States; <sup>4</sup>Pharmaceutical Research Division, Shionogi & Co., Ltd., Osaka, Japan; <sup>5</sup>Clinical Development and Medical Affairs, ID3C, LLC, Easton Connecticut, United States.